Reimb for Verzenio in early breast cancer undergoes review
By Eo, Yun-Ho | translator Kim, Jung-Ju
24.03.05 17:12:29
°¡³ª´Ù¶ó
0
Second attempt since failing to set reimbursement standards the past year
Confirmed additional benefit through 5-year monarchE data
According to a report, the agenda of reimbursing Lilly Korea¡¯s Verzenio (abemaciclib) will be presented to the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee today (March 6).
Therefore, the industry¡¯s attention is on whether Verzenio will succeed in its second reimbursement attempt.
The company had difficulty reaching the CDDC stage during its first attempt for reimbursement in early breast cancer. After a long 6-month wait after submitting the application, the case reache
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)